Modulation of the Effect of Cisplatin on Nicotine-Stimulated A549 Lung Cancer Cells Using Analog of Marine Sponge Toxin Loaded in Gelatin Nanoparticles.

APS12-2 chemotherapeutic agent marine toxin nAChR nAChR antagonist

Journal

Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216

Informations de publication

Date de publication:
30 Apr 2024
Historique:
received: 31 03 2024
revised: 24 04 2024
accepted: 26 04 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 10 5 2024
Statut: epublish

Résumé

Nicotine activates nicotinic acetylcholine receptors (nAChRs), which are overexpressed in numerous cancer types, leading to signaling pathways that increase lung cancer invasiveness and resistance to chemotherapeutic agents. In this study, the effects of APS12-2, a synthetic analog of marine sponge toxin that acts as an antagonist of nAChRs, was investigated in vitro on A549 human lung adenocarcinoma cells and non-tumorigenic human lung epithelial BEAS-2B cells. In addition, gelatin nanoparticles (GNPs) loaded with APS12-2 (APS12-2-GNPs) were prepared and their effects were compared with those of free APS12-2. Nicotine reduced cytotoxicity, the formation of reactive oxygen species, and the formation of lipid droplets caused by cisplatin on A549 cells. The effects of nicotine on the decreased efficacy of cisplatin were reduced by APS12-2 and APS12-2-GNPs. APS12-2-GNPs showed a substantial advantage compared with free APS12-2; the cytotoxicity of APS12-2 on BEAS-2B cells was greatly reduced when APS12-2 was loaded in GNPs, whereas the cytotoxicity on A549 cells was only slightly reduced. Our results suggest that both APS12-2 and APS12-2-GNPs hold promise as supportive agents in the cisplatin-based chemotherapy of lung cancer.

Identifiants

pubmed: 38727371
pii: nano14090777
doi: 10.3390/nano14090777
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : SLOVENIAN RESEARCH AND INNOVATION AGENCY
ID : J4-4550
Organisme : SLOVENIAN RESEARCH AND INNOVATION AGENCY
ID : J2-3052
Organisme : SLOVENIAN RESEARCH AND INNOVATION AGENCY
ID : J3-2520
Organisme : SLOVENIAN RESEARCH AND INNOVATION AGENCY
ID : P1-0207
Organisme : SLOVENIAN RESEARCH AND INNOVATION AGENCY
ID : P2-0424
Organisme : SLOVENIAN RESEARCH AND INNOVATION AGENCY
ID : Z1-2634

Auteurs

Ahmad Joukhan (A)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
Department of Biology, Faculty of Biotechnical, University of Ljubljana, 1000 Ljubljana, Slovenia.

Veno Kononenko (V)

Department of Biology, Faculty of Biotechnical, University of Ljubljana, 1000 Ljubljana, Slovenia.

Marija Sollner Dolenc (M)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.

Matej Hočevar (M)

Institute of Metals and Technology, 1000 Ljubljana, Slovenia.

Tom Turk (T)

Department of Biology, Faculty of Biotechnical, University of Ljubljana, 1000 Ljubljana, Slovenia.

Damjana Drobne (D)

Department of Biology, Faculty of Biotechnical, University of Ljubljana, 1000 Ljubljana, Slovenia.

Classifications MeSH